Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SMTI

SMTI - Sanara MedTech Inc. Stock Price, Fair Value and News

$21.36+0.56 (+2.69%)
Market Closed

70/100

SMTI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

70/100

SMTI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$31.8

Target 3M

$23.92

Target 6M

$26.3

SMTI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SMTI Price Action

Last 7 days

-6.3%

Last 30 days

-11.9%

Last 90 days

-25.9%

Trailing 12 Months

-43.2%

SMTI RSI Chart

SMTI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SMTI Valuation

Market Cap

190.9M

Price/Earnings (Trailing)

-5.09

Price/Sales (Trailing)

2.43

EV/EBITDA

66.81

Price/Free Cashflow

-226.67

SMTI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$31.8

Target 3M

$23.92

Target 6M

$26.3

SMTI Fundamentals

SMTI Revenue

Revenue (TTM)

78.1M

Rev. Growth (Yr)

21.51%

Rev. Growth (Qtr)

4.63%

SMTI Earnings

Earnings (TTM)

-37.5M

Earnings Growth (Yr)

-964.16%

Earnings Growth (Qtr)

-1.4K%

SMTI Profitability

Operating Margin

89.88%

EBT Margin

-9.46%

Return on Equity

-609.3%

Return on Assets

-52.7%

Free Cashflow Yield

-0.44%

SMTI Investor Care

Shares Dilution (1Y)

2.23%

Diluted EPS (TTM)

-4.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
202468.0M72.4M78.1M0
202353.6M59.6M62.6M65.0M
202226.9M30.3M37.6M45.8M
202115.6M18.9M20.4M24.1M
202015.8M15.7M17.1M17.1M
20196.4M7.1M8.5M11.8M
20186.7M7.5M7.5M5.8M
20176.0M6.2M6.4M6.3M
20163.5M4.0M4.5M5.5M
20153.0M3.2M3.4M3.4M
20142.0M2.2M2.4M2.6M
20131.4M1.6M1.7M1.7M
20121.4M1.4M1.6M1.2M
20111.2M1.6M1.9M2.2M
2010000910.4K
Get all data in R, Python etc through our Historical Stock Data APIs

About Sanara MedTech Inc.

SMTI
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
 WEBSITEhttps://sanaramedtech.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES101

Sanara MedTech Inc. Frequently Asked Questions

SMTI is the stock ticker symbol of Sanara MedTech Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Sanara MedTech Inc. is 190.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SMTI's fair value in chart for subscribers.

The fair value guage provides a quick view whether SMTI is over valued or under valued. Whether Sanara MedTech Inc. is cheap or expensive depends on the assumptions which impact Sanara MedTech Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SMTI.

As of Wed Jan 28 2026, SMTI's PE ratio (Price to Earnings) is -5.09 and Price to Sales (PS) ratio is 2.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SMTI PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Sanara MedTech Inc. has provided 0.135 (multiply by 100 for percentage) rate of return.